MedTrace Logo

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

NCT00116142 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2022-01-11

Study results available
· View outcomes & findings →

Summary

This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.

Conditions

Interventions

DRUG

Docetaxel

60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.

DRUG

Androgen Hormonal Suppression and Radiation

Total Androgen Ablation and external beam radiation therapy

DRUG

Androgen Suppression Therapy and Radiation Therapy

Total Androgen Ablation and External Beam Radiation Therapy

Sponsors & Collaborators

Principal Investigators

  • Anthony V. D'Amico, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2020-06-29
Completion
2020-06-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116142 on ClinicalTrials.gov